Allan Oberman, senior vice president of North America Generic Pharmaceuticals of Teva, has been promoted to president and chief executive of Teva Americas Generics as part of a management succession. He will report to Jeremy Levin, president and chief executive of Teva, and have continued responsibility for North America Generics as well as overall management of Teva’s Latin American businesses.
William Marth is to retire as president and ceo of Teva Americas at the end of 2013, but will stay on as senior advisor to Levin until then.
Jill DeSimone has also been appointed to the newly created position of senior vice president and general manager of Teva Global Women’s Health, overseeing all aspects of this franchise.
‘These changes are part of our ongoing process to build a premier leadership team and reshape Teva,’ said Levin.
Oberman has been SVP of North America Generic Pharmaceuticals since earlier this year. He joined Teva in 2000 and has served as president of Teva EMIA (Eastern Europe, Middle East, Israel and Africa); chief operating officer of the Teva International Group and president and CEO of Teva Canada. Prior to this he was president of Best Foods Canada. He also served as chairman of the Canadian Generic Pharmaceutical Association in 2007–2008.
DeSimone joins Teva from Bristol-Myers Squibb (BMS), where she has held various global leadership positions, most recently as senior vice president, US Commercialisation Excellence.
She also held previous roles in BMS’ US Oncology and Virology business units, where she developed a number of important franchises.
